HIV preexposure prophylaxis for adolescents and young adults. Issue 4 (August 2017)

• Record Type: Journal Article
• Authors: Allen, Emily; Gordon, Allegra; Krakower, Douglas; Hsu, Katherine
• Is Part Of: Current opinion in pediatrics. Volume 29:Issue 4(2017:Aug.)
• Publication Date: 2017-08
• Subjects: adolescent -- HIV -- preexposure prophylaxis -- youth; Pediatrics -- Periodicals; Pediatrics -- Periodicals -- Bibliography -- Periodicals; 618.92
• DOI: 10.1097/MOP.0000000000000512
• Languages: English
• ISSNs: 1040-8703

Abstract

Abstract : Purpose of review: The review describes the evidence for HIV preexposure prophylaxis (PrEP) with daily combined tenofovir disoproxil fumarate and emtricitabine for adolescents and young adults. Current recommendations are described, as are the unique medical, socioeconomic, and legal considerations regarding the use of PrEP for youth. Recent findings: PrEP with daily oral tenofovir disoproxil fumarate–emtricitabine has been shown to help prevent new HIV infection among adults at substantial risk. Evidence suggests a protective benefit of PrEP for youth at risk for HIV, although low adherence is emerging as a barrier to effective use. Summary: Effective use of antiretrovirals for PrEP represents a seminal development in HIV prevention efforts. Improving access and adherence to PrEP for youth has the potential to substantially reduce the incidence of HIV in this population.